Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 24 09 2019
accepted: 08 09 2020
entrez: 24 9 2020
pubmed: 25 9 2020
medline: 13 11 2020
Statut: epublish

Résumé

Antiretroviral therapy (ART) has revolutionised the care of HIV-positive individuals resulting in marked decreases in morbidity and mortality, and markedly reduced transmission to sexual partners. However, these benefits can only be realised if individuals are aware of their HIV-positive status, initiated and retained on suppressive lifelong ART. Framed using the socio-ecological model, the present study explores factors contributing to poor ART uptake among community members despite high acceptance of HIV-testing within a Treatment as Prevention (TasP) trial. In this paper we identify barriers and facilitators to treatment across different levels of the socio-ecological framework covering individual, community and health system components. This research was embedded within a cluster-randomised trial (ClinicalTrials.gov, number NCT01509508) of HIV treatment as Prevention in rural KwaZulu-Natal, South Africa. Data were collected between January 2013 and July 2014 from resident community members. Ten participants contributed to repeat in-depth interviews whilst 42 participants took part in repeat focus group discussions. Data from individual interviews and focus group discussions were triangulated using community walks to give insights into community members' perception of the barriers and facilitators of ART uptake. We used thematic analysis guided by a socio-ecological framework to analyse participants' narratives from both individual interviews and focus group discussions. Barriers and facilitators operating at the individual, community and health system levels influence ART uptake. Stigma was an over-arching barrier, across all three levels and expressed variably as fear of HIV disclosure, concerns about segregated HIV clinical services and negative community religious perceptions. Other barriers were individual (substance misuse, fear of ART side effects), community (alternative health beliefs). Facilitators cited by participants included individual (expectations of improved health and longer life expectancy following ART, single tablet regimens), community (availability of ART in the community through mobile trial facilities) and health system factors (fast and efficient service provided by friendly staff). We identified multiple barriers to achieving universal ART uptake. To enhance uptake in HIV care services, and achieve the full benefits of ART requires interventions that tackle persistent HIV stigma, and offer people with HIV respectful, convenient and efficient services. These interventions require evaluation in appropriately designed studies.

Identifiants

pubmed: 32970730
doi: 10.1371/journal.pone.0239513
pii: PONE-D-19-24632
pmc: PMC7514038
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

ClinicalTrials.gov
['NCT01509508']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0239513

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Déclaration de conflit d'intérêts

I have updated the competing interest statement in the text of the manuscript. Revised text below I have read the journal's policy and the authors of this manuscript have the following competing interests: CI received research grants, honoraria for consulting services and conference attendance support from Gilead Sciences. All other authors declare that they have no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

PLoS One. 2017 Jun 15;12(6):e0178249
pubmed: 28617805
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
BMC Public Health. 2009 Mar 04;9:75
pubmed: 19261186
PLoS One. 2010 Jul 12;5(7):e11539
pubmed: 20634965
JAMA. 2017 Jun 6;317(21):2196-2206
pubmed: 28586888
PLoS One. 2018 Oct 16;13(10):e0203193
pubmed: 30325932
BMC Public Health. 2008 Feb 18;8:63
pubmed: 18282286
PLoS One. 2013;8(2):e56088
pubmed: 23418518
Front Public Health. 2018 Mar 12;6:73
pubmed: 29594094
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
PLoS One. 2018 Aug 30;13(8):e0202990
pubmed: 30161172
Demogr Res. 2009 Jun 30;20:279-312
pubmed: 25729322
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25117
pubmed: 30027643
BMC Public Health. 2016 Jan 28;16:87
pubmed: 26823077
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
BMJ. 1995 Jul 29;311(7000):299-302
pubmed: 7633241
Glob Health Sci Pract. 2015 Mar 05;3(1):109-16
pubmed: 25745124
J Int AIDS Soc. 2015 May 27;18:19984
pubmed: 26022654
Health Place. 2019 Jan;55:87-99
pubmed: 30528346
Man Ther. 2012 Oct;17(5):378-84
pubmed: 22480949
Biomed Res Int. 2018 Mar 21;2018:9619684
pubmed: 29750175
BMC Public Health. 2016 Feb 16;16:155
pubmed: 26880423
N Engl J Med. 2019 Jul 18;381(3):219-229
pubmed: 31314966
J Int AIDS Soc. 2012 Nov 19;15(2):17383
pubmed: 23199799
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29314658
Trials. 2014 Feb 13;15:57
pubmed: 24524229
Am Psychol. 2013 May-Jun;68(4):210-24
pubmed: 23688089
J Int AIDS Soc. 2016 Jun 01;19(1):20913
pubmed: 27258430
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet HIV. 2016 Mar;3(3):e111-9
pubmed: 26939734
AIDS Patient Care STDS. 2013 Apr;27(4):231-41
pubmed: 23530573
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
AIDS Behav. 2019 Apr;23(4):929-946
pubmed: 30415432
J Int AIDS Soc. 2013 Nov 13;16(3 Suppl 2):18734
pubmed: 24242268
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
BMC Public Health. 2015 Mar 01;15:209
pubmed: 25880823
BMJ Open. 2018 Feb 21;8(2):e017955
pubmed: 29467131
J AIDS Clin Res. 2015 Nov 30;6:
pubmed: 27774350
Curr HIV/AIDS Rep. 2013 Dec;10(4):324-32
pubmed: 23996649
N Engl J Med. 2019 Jul 18;381(3):286-288
pubmed: 31314975
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
Afr J AIDS Res. 2018 Sep;17(3):217-225
pubmed: 30132397
AIDS Behav. 2015 Jan;19(1):137-44
pubmed: 25034940

Auteurs

Collins Iwuji (C)

Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, United Kingdom.
Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.

Rujeko Samanthia Chimukuche (RS)

Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.

Thembelihle Zuma (T)

Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.

Melanie Plazy (M)

Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.

Joseph Larmarange (J)

Institut de Recherche pour le Développement(IRD), Centre Population et Développement (Ceped), Paris, France.

Joanna Orne-Gliemann (J)

Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.

Mark Siedner (M)

Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Harvard Medical School, Boston, Massachusetts, United States of America.

Maryam Shahmanesh (M)

Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Institute for Global Health, University College London, London, United Kingdom.

Janet Seeley (J)

Africa Health Research Institute, Berea, KwaZulu-Natal, South Africa.
London School of Hygiene and Tropical Medicine, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH